Neurodegenerative disease management · 2018
Treatment and comorbidities of multiple sclerosis in an employed population in Japan: analysis of health claims data.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogino Mieko, Shiozawa Aki, Ota Hiroyuki, Okamoto Shuichi, Hiroi Shinzo, Kawachi Izumi
Аннотация
AIM: Use real-world data to investigate the treatment, comorbidities and prevalence of multiple sclerosis (MS) in an employed Japanese population.
METHODS: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-β and prednisolone were the most commonly prescribed treatments. Common comorbidities included astigmatism and gastric ulcer. Within the database, MS prevalence increased from 0.015 to 0.016%.
CONCLUSION: MS prevalence increased from 2011 to 2013. Some comorbidities were considered unrelated to MS owing to how physicians use disease codes for reimbursement.
METHODS: Data from the Japanese Medical Data Center health insurance claims database were analyzed (January 2005-November 2014). Patients with claims associated with an MS diagnosis were identified (n = 494) and comorbidities and prescribed treatments were investigated. MS prevalence within the database was calculated for each calendar year (2011-2013) Results: IFN-β and prednisolone were the most commonly prescribed treatments. Common comorbidities included astigmatism and gastric ulcer. Within the database, MS prevalence increased from 0.015 to 0.016%.
CONCLUSION: MS prevalence increased from 2011 to 2013. Some comorbidities were considered unrelated to MS owing to how physicians use disease codes for reimbursement.